Dermocosmetic  ||| S:0 E:14 ||| JJ
management  ||| S:14 E:25 ||| NN
of  ||| S:25 E:28 ||| IN
the  ||| S:28 E:32 ||| DT
red  ||| S:32 E:36 ||| JJ
face  ||| S:36 E:41 ||| NN
and  ||| S:41 E:45 ||| CC
rosacea  ||| S:45 E:53 ||| JJ
Erythematotelangiectatic  ||| S:53 E:78 ||| JJ
rosacea  ||| S:78 E:86 ||| NN
is  ||| S:86 E:89 ||| VBZ
a  ||| S:89 E:91 ||| DT
frequent  ||| S:91 E:100 ||| JJ
condition  ||| S:100 E:110 ||| NN
and  ||| S:110 E:114 ||| CC
affected  ||| S:114 E:123 ||| JJ
patients  ||| S:123 E:132 ||| NNS
benefit  ||| S:132 E:140 ||| VBP
from  ||| S:140 E:145 ||| IN
medical  ||| S:145 E:153 ||| JJ
treatments  ||| S:153 E:164 ||| NNS
and  ||| S:164 E:168 ||| CC
dermatological  ||| S:168 E:183 ||| JJ
procedures  ||| S:183 E:194 ||| NNS
but  ||| S:194 E:198 ||| CC
also  ||| S:198 E:203 ||| RB
a  ||| S:203 E:205 ||| DT
complementary  ||| S:205 E:219 ||| JJ
dermocosmetic  ||| S:219 E:233 ||| JJ
assistance  ||| S:233 E:244 ||| NN
that  ||| S:244 E:249 ||| WDT
aims  ||| S:249 E:254 ||| VBZ
at  ||| S:254 E:257 ||| IN
obtaining  ||| S:257 E:267 ||| VBG
optimal  ||| S:267 E:275 ||| JJ
skin  ||| S:275 E:280 ||| NN
comfort  ||| S:280 E:288 ||| NN
and  ||| S:288 E:292 ||| CC
preventing  ||| S:292 E:303 ||| VBG
irritation  ||| S:303 E:314 ||| NN
of  ||| S:314 E:317 ||| IN
these  ||| S:317 E:323 ||| DT
particularly  ||| S:323 E:336 ||| RB
overreactive  ||| S:336 E:349 ||| JJ
skins ||| S:349 E:354 ||| NNS
.  ||| S:354 E:356 ||| .
Choice  ||| S:356 E:363 ||| NN
of  ||| S:363 E:366 ||| IN
dermocosmetics  ||| S:366 E:381 ||| NN
is  ||| S:381 E:384 ||| VBZ
crucial  ||| S:384 E:392 ||| JJ
-  ||| S:392 E:394 ||| :
especially  ||| S:394 E:405 ||| RB
in  ||| S:405 E:408 ||| IN
respect  ||| S:408 E:416 ||| NN
to  ||| S:416 E:419 ||| TO
their  ||| S:419 E:425 ||| PRP$
texture  ||| S:425 E:433 ||| NN
and  ||| S:433 E:437 ||| CC
the  ||| S:437 E:441 ||| DT
simplicity  ||| S:441 E:452 ||| NN
in  ||| S:452 E:455 ||| IN
ingredients  ||| S:455 E:467 ||| NNS
-  ||| S:467 E:469 ||| :
in  ||| S:469 E:472 ||| IN
order  ||| S:472 E:478 ||| NN
to  ||| S:478 E:481 ||| TO
optimize  ||| S:481 E:490 ||| VB
the  ||| S:490 E:494 ||| DT
application  ||| S:494 E:506 ||| NN
of  ||| S:506 E:509 ||| IN
the  ||| S:509 E:513 ||| DT
products  ||| S:513 E:522 ||| NNS
and  ||| S:522 E:526 ||| CC
their  ||| S:526 E:532 ||| PRP$
tolerance ||| S:532 E:541 ||| NN
.  ||| S:541 E:543 ||| .
The  ||| S:543 E:547 ||| DT
addition  ||| S:547 E:556 ||| NN
of  ||| S:556 E:559 ||| IN
soothing  ||| S:559 E:568 ||| NN
and  ||| S:568 E:572 ||| CC
decongestant  ||| S:572 E:585 ||| JJ
active  ||| S:585 E:592 ||| JJ
ingredients  ||| S:592 E:604 ||| NNS
is  ||| S:604 E:607 ||| VBZ
particularly  ||| S:607 E:620 ||| RB
important ||| S:620 E:629 ||| JJ
.  ||| S:629 E:631 ||| .
Finally ||| S:631 E:638 ||| RB
,  ||| S:638 E:640 ||| ,
photoprotection  ||| S:640 E:656 ||| NN
and  ||| S:656 E:660 ||| CC
a  ||| S:660 E:662 ||| DT
specific  ||| S:662 E:671 ||| JJ
medical  ||| S:671 E:679 ||| JJ
make-up  ||| S:679 E:687 ||| NNS
are  ||| S:687 E:691 ||| VBP
useful  ||| S:691 E:698 ||| JJ
to  ||| S:698 E:701 ||| TO
attenuate  ||| S:701 E:711 ||| VB
the  ||| S:711 E:715 ||| DT
unattractive  ||| S:715 E:728 ||| JJ
appearance  ||| S:728 E:739 ||| NN
of  ||| S:739 E:742 ||| IN
red  ||| S:742 E:746 ||| JJ
faces ||| S:746 E:751 ||| NNS
.  ||| S:751 E:753 ||| .
